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III PREFACE 
 
Bleeding secondary to civilian injuries and trauma and war injuries remain a significant 
cause  of mortality in a pre-hospital setting. Intra-operative bleeding also cause significant 
mortality and prolong hospital stay. Several hematological conditions such as 
thrombocytopenia and disseminated intravascular coagulation further complicate patients 
condition and prolong bleeding and clotting time.  
 
Chitosan has been shown through several previous studies to be superior comparative to 
common surgical hemostats currently available. Chitosan molecular weight and 
deacetylation degree affects its haemostatic potential. The greater  the degree of 
deacetylation the better its haemostatic potential. It has been shown through several studies 
to induce hemostasis through its action on platelet aggregation and red cell aggregation. In 
addition, chitosan has been also shown to induce vasoconstriction and hence also 
contribute to hemostasis.  
 
In this study we compared several different grades of chitosan prepared by SIRIM® 
Malaysia, with the currently present surgical haemostatic agents in the operation theatre or 
the surgical wards and emergency department. We also wanted to examine the effects of 
these haemostatic agents on platelet aggregation and red cell aggregation in vitro. It is 
hoped that this study could serve as a guide for proper selection of haemostatic agents for 
each clinical scenario. It is expected that it would prove that chitosan based dressings as 
superior if not equal to the commonly present hemostats. 
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VIII  ABSTRAK 
 
 
 
Kegagalan untuk memberhentikan pendarahan dengan sempurna adalah punca paling 
utama  pendarahan intraoperatif . Hampir semua tinjauan  pendarahan intraoperatif dan 
awal post-operatif menunjukan  75% hingga 90% dari pendarahan semua disebabkan 
punca teknikal. Pendarahan yang tidak terkawal menjadi punca  kombinasi beberapa faktor 
yang boleh menyebabkan pendarahan yang berlanjutan. Pendarahan yang berterusan boleh 
juga disebabkan oleh masalah kekurangan sel platelet atau fungsi pembekuan darah yang 
terganggu. Ini merumitkan lagi usaha memberhentikan pendarahan. Penyelidikan kami 
adalah bertujuan untuk membandingkan keberkesanan produk kitosan dengan produk 
hemostat lain, yang biasa digunakan di dewan bedah. Hipotesis kami adalah bahawa 
hemostat berasaskan kitosan lebih unggul berbanding hemostat bedah yang lain dalam 
menyebabkan agregasi platelet dan sel-sel darah merah dan juga dalam mempengaruhi 
Prothrombin Time dan Partial Thromboplastin Time. 
 
 
Kajian kami dibahagikan kepada dua bahagian. Dalam kajian in-vitro,  sampel darah yang 
diperolehi dari bank darah diproses menggunakan sistem CP2D/AS-3 dengan larutan aditif 
(AS-3, Nutricel ®). Darah yang dikumpul telah dipisahkan kepada empat komponen iaitu 
darah utuh, darah utuh dicampur heparin, plasma kaya platelet, dan plasma yang 
mempunyai jumlah platelet yang sedikit. Dalam ujian platelet aggregation,   PRP sitrat 
dicampurkan dengan 3.5 mg  agen hemostatik yang dilembabkan dengan 100 liter mikro 
phosphate buffered saline (PBS) dalam tabung uji. 100 mikroliter supernatan (100 liter 
mikro) telah diambil setiap 5 minit untuk kesuluruhan 15 minit dan jumlah platelet disukat 
menggunakan counter sel elektronik (XT2000i Sysmax Analyzer, Sysmex America Inc, 
Mundelein, Illinois). Jumlah platelet dari setiap  percubaan dinormalisasi menggunakan 
jumlah platelet dari PRP kawalan . Untuk setiap agen hemostatik, tiga set kajian 
dilakukan. Ujian ini telah diulang untuk setiap agen hemostatik yang dikaji. Dalam ujian 
PT/PTT agen-agen hemostatik ditindak balaskan dengan plasma kaya platelet dan plasma 
kurang platelet. Serum tersebut telah  disentrifugasi untuk menghilangkan deposit yang 
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terkandung dalam plasma tersebut.. Percubaan ini telah diulang sebanyak enam kali dan 
kajian telah dilakukan keatas Prothrombin Time and Partial Thromboplastin Time 
menggunakan mesin penganalisis hemostasis (Stago STA Compact hemostatik Analyzer, 
Diamond Diagnostik, MA. USA)  
 
Dalam ujian agregasi sel darah merah, setiap agen hemostatik telah ditindak balaskan 
dengan utuh, darah dicampur heparin dan darah kurang platelet. Darah dengan agen 
hemostatik dibiarkan berinteraksi dan tahap sedimentasi sel-sel darah merah diukur dengan 
mesin penganalisis sedimentasi Sedy400.  
 
Dalam experiment invivo pula, 36 ekor tikus Sprague-Dawley telah digunakan. Tikus tikus 
tersebut telah dibius sebelum melakukan pembedahan. Pembedahan laporotomi telah 
dilakukan untuk mendedahkan kedua-dua ginjal tikus tersebut. Heminephrectomies 
dilakukan dan agen hemostat diterapkan ke permukaan yang dipotong. Masa yang 
diperlukan setiap agen hemostat untuk memberhentikan pendarahan tersebut diukur.  
 
Dalam ujian agregasi platelet, didapati tidak ada trend yang jelas dalam fungsi agen-agen 
hemostatik tersebut dalam mengumpul atau mengagregasi platelet. No CMC 36 3% 
menunjukkan jumlah platelet terendah berbanding  agen-agen hemostatik yang lain dalam  
5 minit yang pertama ujian tersebut. Lyostypt ® dan Surgicel ® lebih unggul berbanding 
dengan agen hemostat kitosan pada masa 10 minit kajian tersebut. 
 
Dalam ujian PT / PTT, prothrombin time untuk Chitosan (NoCMC 8%) adalah yang 
terpendek dalam plasma kaya dengan platelet.  Dalam plasma kurang platelet pula, masa 
protrombin terpendek dilihat pada kedua-dua hemostat Chitosan (NoCMC 3% dan 
NoCMC8%). Partial thromboplastin time didapati terpendek untuk agen Chitosan 
(NoCMC 3%) .  
 
Dalam ujian agregasi sel darah merah, agen hemostat Chitosan (NoCMC 3%) 
menunjukkan nisbah tertinggi sedimentasi sel-sel darah merah  dalam darah  kurang 
platelet serta spesimen darah dicampur heparin. Agen hemostat Chitosan (NoCMC 8%) 
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menunjukkan nisbah tertinggi sedimentasi sel-sel darah merah dalam darah utuh di campur 
heparin. 
 
Dalam eksperimen invivo pula, didapati tidak ada perbezaan statistik yang ketara antara 
kesemua agen-agen hemostatik dalam mengurangkan  pendarahan dari spesimen 
heminephrectomy. Agen hemostat Chitosan (NoCMC 36 3%) bagaimanapun berjaya 
memberhentikan pendarahan pada ginjal tikus dalam tempoh masa yang terpendek 
dibandingkan dengan agen-agen hemostatik yang lain. 
 
Dari kajian-kajian yang telah dijalankan kami berpendapat bahawa agen hemostatik 
Chitosan hemostat menyebabkan agregasi platelet lebih awal, memendekkan Prothrombin 
dan Partial Thromboplastin Time lebih awal berbanding agen hemostatik yang lain. 
Mereka juga lebih baik berbanding agen hemostatik yang lain dalam menyebabkan 
agregasi sel-sel darah merah dalam proses pembekuan darah.  
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IX ABSTRACT 
 
The most common cause of significant intra-operative bleeding is inadequate surgical 
hemostasis. Nearly all reviews of intra-operative and early post-operative bleeding point 
that 75% to 90% of all bleeding is technical in nature. Whatever the cause, uncontrolled 
bleeding can lead to a combination of factors which may further exacerbate the problem of 
a vicious bloody circle. Dilutional thrombocytopenia, platelet dysfunction and 
consumption of clotting factors present a difficult problem to address as continual blood 
loss continue to compound the problem while blood component replacement therapy 
attempts to correct the deficiency. Our study aims to compare haemostatic efficacy of 
different grades of chitosan compared to the common haemostatic surgical hemostats.  We 
hypothesize that chitosan based hemostats are superior to the common surgical hemostats 
in inducing platelet aggregation, affecting Prothrombin Time and Partial Thromboplastin 
Time and red cell aggregation.  
 
There were two parts to the study. In the in vitro study blood sample was obtained from the 
blood bank. Blood sample was collected utilizing the CP2D/AS-3 systems with additive 
solution (AS-3,Nutricel® ) to maintain red blood cell viability. Collected whole blood was 
separated into four separate components ( whole blood, heparinized whole blood, platelet 
rich and platelet poor plasma) . In the platelet aggregation test, stirred citrated PRP was 
contacted with 3.5 mg of each haemostatic agent premoistened with 100 micro liter of 
phosphate-buffered saline (PBS) in a test tube (as would be used in traditional platelet 
aggregometry). Aliquots of supernatant (100 micro liter) were removed every 5 minute for 
a total of 15 minutes and the platelet count was measured in triplicate utilizing an 
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electronic cell counter (XT2000i Sysmax Analyzer, Sysmex America Inc.,  Mundelein, 
Illinois); platelet counts from each experimental aliquot were normalized using counts 
from unreacted PRP. For each haemostatic agent three independent sets of experiments 
were performed. A similar set of platelet aggregation experiments was performed using the 
haemostatic sponge agents ( 3 Different grades of Chitosan, Lyostypt® , and Surgicel®) 
premoistened with PBS. In the PT/PTT test, each haemostatic agent was reacted with 
platelet rich and platelet poor plasma.  The serum was centrifuged to remove possible 
deposition. Six parallel experiments were conducted to measure PT and APTT of the 
serum using a hemostasis analyzer (Stago STA Compact Haemostatic Analyzer, Diamond 
Diagnostics, MA. USA) In the red cell aggregation test, each haemostatic agent was 
reacted with whole blood, heparinized blood and platelet poor blood. The blood with 
haemostatic agents were left to stand and the erythrocyte sedimentation rate was measured 
with the Sedy400 sedimentation analyzer. In the animal experiment, 36 Sprague-Dawley 
rats were utilized. Under general anesthesia, via a midline laparotomy the right and left 
kidneys were isolated. Heminephrectomies were carried out and hemostats were applied to 
the cut surface and time taken to hemostasis was tabulated.  
In the platelet aggregation test, no definite trend in platelet aggregation was observed. No 
CMC 36 3% showed the lowest platelet count of all haemostatic agents at 5 minutes. 
Lyostypt® and Surgicel® were superior compared to chitosan hemostats at 10 minutes of 
contact.  
 
In the coagulation test (PT/PTT ) mean prothrombin time for Chitosan (NoCMC 8%) was 
the shortest in platelet rich plasma. Mean partial thromboplastin time was the shortest for 
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Chitosan (NoCMC 3%) in platelet rich plasma. In platelet poor plasma, the shortest 
prothrombin time was seen in both the Chitosan hemostats( NoCMC 3% and NoCMC8%). 
Partial thromboplastin time was shortest for Chitosan (NoCMC 3%) hemostat. In the red 
cell aggregation test, Chitosan hemostat(NoCMC 3%) demonstrated the highest 
erythrocyte sedimentation ratio in platelet poor blood as well as heparinized blood 
specimens. Chitosan hemostat (NoCMC 8%) demonstrated the highest erythrocyte 
sedimentation ratio in heparinized whole blood. 
 
In the animal experiment, there was no statistical difference between the hemostats in 
arresting bleeding from heminephrectomy specimens. The Chitosan hemostat(NoCMC 36 
3%)  however demonstrated the shortest time to hemostasis compared to the other 
hemostats.  
 
From the study we concluded that Chitosan hemostats causes platelet to aggregate the 
earliest compared to other hemostats. They  shorten prothrombin and partial 
thromboplastin time. They have been also found to aggregate red blood cells the most 
compared to other haemostatic agents.  
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1.0 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Research background 
 
Bleeding, technically known as hemorrhaging, is the loss of blood or blood escape from 
the circulatory system. It is a likely complication of any surgical procedure or trauma and 
introduces a challenge to the surgical and anesthetic teams. The grimness of bleeding can 
vary from Class I to a Class IV (15% to 40% and more of blood volume lost) .Mortality 
from bleeding in surgery can be increased from 1% to 20% when severe, unexpected and 
uncontrollable bleeding occurs. Liver and cardiac surgeries are associated with profuse 
hemorrhage and clinical experience and observational studies have shown that massive 
blood loss is linked to adverse outcomes and that 75% to 90% of intra-operative and early 
postoperative bleeding is affected by surgical technique(Marietta et al., 2006).  
Uncontrollable hemorrhage also accounts for almost 50% of combat fatalities and up to 
80% of civilian trauma fatalities within the United States. In settings such as these, 
around 30-40% of trauma related deaths(Sauaia et al., 1995) and more than 90% of 
combat deaths take place in the pre-hospital setting(Champion et al., 2003). Extremity 
injuries can be sufficiently treated with tourniquet placement. In a proximal limb injury a 
tourniquet can be hard to apply. Other areas in the body require manual compression 
which requires both personnel time and commitment(Gustafson et al., 2007) . The use of 
these maneuvers in a pre-hospital setting can substantially increase the survival of trauma 
patients with uncontrolled hemorrhage(Pusateri et al., 2006).  
 
 3 
1.2 Hemostasis 
 
1.2.1 History of hemostasis 
 
Hemostasis is traced from the primitive man's realization that unchecked bleeding meant 
death up to Lister's experiments developing the present day absorbable ligature. The early 
Greeks and Romans used vegetable and mineral styptics on wounds received in battle; it 
was with these that Macheon ministered to Menelaus before the walls of Troy. Then the 
early surgeon began to make intentional incisions, but avoiding the blood vessels as they 
were uncovered. Not content with their own domain, the Greeks invaded Egypt and 
became familiar with the dissection known to the Egyptians. 
 
 Herophilus described the vessels as veins filled with blood and the arteries filled with 
blood and "pneuma", and he noted the difference in the walls of the two kinds of vessels. 
At the time of Celsus, ligature was advised as a last resort, only after the cautery and 
styptics had failed. Galen, during the decline and fall of the Roman empire, wrote a 
description of the circulation, remarkably close to the modern conception, and favored 
the cautery for hemostasis(Atterbury, 1976). 
 
In the West, little progress was made until the fifteenth century. At that time, gun powder 
was invented and the incidence of battle wounds increased for the army surgeon. The 
printing-press launched forth medical, surgical, and scientific texts, and for the first time 
there was a chance for the operator to study the notes of others, and knowledge was more 
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widely disseminated. There were two differing schools of thoughts regarding healing. 
One, by first intention and the other by suppuration. Ambrose Pare, by accident, 
discovered that wounds left to “autodigest” healed better than wounds that were 
cauterized. He modestly described his first cure by saying that, "I dressed him and God 
healed him". Pare also described the bec de corbin, a pinching instrument for holding 
blood vessels. Morel is accredited with the invention, in I674, of the twisted stick 
tourniquet(Atterbury, 1976). A spring was added to the bec de corbin and rolls of 
bandage were placed under the tourniquet to press on the great vessels. Amputation 
became more frequent and coagulation of the blood was described by Jones and Lawson. 
Physick and Nathan Smith first had the courage to cut short the ends of their buckskin 
ligatures, contrary to the advice and teachings of Liston(Atterbury, 1976).  
 
The forceps were gradually improved and Kocher and Halstead gave their names to their 
designs. Soon it was realized that more than one or two clamps were necessary for an 
operation, and the technique improved. Then Lord Lister introduced the aseptic technique 
and perfected the ligature by sterilization in dilute carbolic acid; the theory of asepsis 
having been supported by Pasteur and Koch(Lidwell, 1987). His experiments were 
thorough and the results were satisfactory as is evidenced by our modern operative 
procedures. Revealing these and many other facts, this text affords an opportunity for a 
pleasant and profitable adventure within the field of medical history(Atterbury, 1976). 
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1.2.2 The coagulation cascade 
 
The modern concept of coagulation was presented in 1964 as the Waterfall/Cascade 
model, which might overwhelm many nonhematologists with its complexity. Coagulation 
proceeds through a series of proteolytic reactions involving trypsin-like enzymes that 
form a biochemical amplifier, culminating in generation of sufficient thrombin to form a 
fibrin clot. Initiation of fibrin formation through the “extrinsic pathway” occurs when 
plasma factor VIIa forms a complex with the integral membrane protein tissue factor. 
Tissue factor is not normally found at high concentrations in blood, but is present on cell 
membranes in sub endothelial layers of blood vessels and is exposed to factor VIIa when 
the endothelium is injured. 
 
 Alternatively, coagulation may be initiated through the “intrinsic pathway” when factor 
XII is activated on a charged surface by a process called contact activation. Activation of 
factor XII is followed sequentially by activation of factor XI and factor IX. The intrinsic 
and extrinsic pathways converge at the level of factor X activation. Factor Xa activates 
prothrombin to thrombin in the presence of the cofactor factor Va, and thrombin 
subsequently converts fibrinogen to fibrin(Romney and Glick, 2009). 
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1.2.2.1  Role of the extrinsic pathway 
 
The TF:FVIIa complex is traditionally referred to as the extrinsic pathway and is 
proposed to be the primary activator of the coagulation protease cascade in vivo. 
Subsequently, propagation of the thrombus involves recruitment of additional platelets 
and amplification of the coagulation cascade by the intrinsic pathway of blood 
coagulation, which includes the hemophilia factors FVIII and FIX. Importantly, platelets 
play a critical role in the amplification of the coagulation cascade by providing a 
thrombogenic surface. Finally, fibrin stabilizes the platelet-rich thrombus(Mackman et 
al., 2007). 
 
 
1.2.2.2  Role of the intrinsic pathway 
 
The intrinsic pathway is typically depicted as a sequence of proteolytic reactions 
culminating in factor IX activation. However, the hemorrhagic phenotypes of patients 
deficient in components of this pathway suggest more complex interactions. Deficiency 
of factor IX or its cofactor, factor VIII, cause hemophilia B and hemophilia A 
respectively. The severe forms of hemophilia A and B are associated with crippling 
hemorrhage into joints and muscles, and soft tissue bleeding that can be life threatening. 
Factor XI deficiency; in contrast, is associated with a distinctly different, and usually 
milder disorder characterized by trauma or soft tissue-related hemorrhage, primarily 
involving tissues with high fibrinolytic activity. Finally, factor XII– deficient patients do 
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not exhibit an abnormal bleeding tendency, even with surgery, despite having markedly 
prolonged PTT clotting times. These observations argue strongly against the 
waterfall/cascade model in which proteases are exclusively activated in a linear 
sequential fashion.(Gailani and Renne, 2007) 
 
1.2.3 Mechanism of platelet aggregation  
 
Platelets adhere to exposed sub endothelial structures in response to alterations in the 
vessel wall, and become rapidly activated by interaction with thrombogenic substrates 
and agonists released or generated locally. In this manner, they acquire the ability to bind 
soluble adhesive molecules that become the reactive surface for continuing platelet 
deposition. Initial platelet tethering to a surface and subsequent platelet-platelet cohesion 
are typically identified as two separate stages of thrombus formation, respectively known 
as adhesion and aggregation. Most of the current concepts of aggregation mechanisms 
derive from experimental models in which platelets are studied in a stirred suspension 
and induced to interact with one another by appropriate stimuli in the absence of a 
reactive surface. In reality, thrombus growth involves the progressive accrual of 
individual platelets that attach to others already adhering at a site of injury. Therefore, 
adhesion and aggregation are related processes, because the initial platelet monolayer 
anchored to the vessel wall plays a key role in determining the progression of thrombus 
growth. This review focuses on recent developments in elucidating the mechanisms that 
regulate platelet aggregation. Central to this process are bidirectional signals induced by 
the binding of one or more agonist ligands to platelet membrane receptors, leading to the  
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modulation of integrin _IIb_3 into a high affinity/avidity binding site for soluble adhesive 
proteins(Savage et al., 2001).  
 
1.2.4  Mechanism of red cell aggregation  
 
Red cell aggregates may form when the cells come into close proximity. One explanation 
often advanced for aggregation is the bridging hypothesis proposed by Chien and Jan  
which postulates that long-chain macromolecules such as fibrinogen or dextrans of high 
molecular weight may be adsorbed onto the surface of more than one cell, leading to a 
bridging effect between cells(Chien and Jan, 1973). It has been proposed by other 
investigators that the reduced concentration of macromolecules in the vicinity of red cells 
lowers the osmotic forces in the vicinity, causing fluid to move away and increasing the 
tendency for adjacent red cells to come together. According to both the bridging and the 
depletion theories, the total adherent force between two cells is maximal when the cells 
are oriented en face, thus it is not uncommon to observe cells arranged in rouleaux. The 
shear stress required to separate two cells in this orientation suspended in 4% dextran 70 
was determined by Chien and coworkers to be less than 1 dyn/cm2(Chien and Jan, 1973). 
The exact configuration of a group of cells depends on local conditions such as shear rate 
and cell concentration (haematocrit) and a variety of complex forms ranging from single 
rouleaux to a branching network of rouleaux to more compact spheroids may be seen.  
Two separate models exist for RBC aggregation: bridging and depletion. In the bridging 
theory, bridging forces due to adhesion of macromolecules to red blood cell surfaces 
overcome repulsive forces such as electrostatic repulsion, membrane strain and 
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membrane shearing. On the other hand the depletion force theory states that a depletion 
of macromolecules around the surface of the red cell creates an osmotic gradient and thus 
creating a depletion interaction. 
 
1.2.5 Hemostats in surgical practice 
 
A fundamental principle of good surgical technique is minimization of blood loss, and 
present day surgeons have a wide variety of agents and tools to aid them in this 
endeavor. Although no aid in hemostasis can negate the importance of good surgical 
technique, even the most talented surgeon has encountered persistent bleeding which has 
required focused attention.  
i) Collagen-based agents trigger platelet aggregation resulting in clot formation when in 
contact with a bleeding surface. They are often combined with a procoagulant substance 
such as thrombin to enhance the haemostatic effect. A positive haemostatic effect has 
been shown in several human studies(Tomizawa, 2005) . 
ii) Gelatin-based products can be used alone or in combination with a procoagulant 
substance(Seyednejad et al., 2008) . Swelling of the gelatin in contact with blood reduces 
the blood flow and, in combination with a thrombin-based component, enhances 
haemostasis. A similar or superior haemostatic effect has been observed with collagen-
based agents. 
 iii) The effect of cellulose-based haemostatic agents on bleeding has been not well 
studied and only case reports that support their use are available. 
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iv) Fibrin and synthetic glues or adhesives have both haemostatic and sealant properties 
and their significant effect on haemostasis have been shown in several human RCTs 
involving vascular, bone, skin and visceral surgery(Wheat and Wolf, 2009). 
v) Polysaccharide-based haemostatic can be divided into two broad categories]: N-acetyl-
glucosamine containing glycosaminoglycans purified from microalgae and diatoms and 
micro porous polysaccharide haemospheres produced from potato starch. The mechanism 
of action is complex and depends on the purity or combination with other substances such 
as cellulose or fibrin. A number of different products are currently available and have 
been shown to be efficient for external use. An observational study showed that 
hemorrhage control was achieved using an N-acetylglucosamine-based bandage applied 
to 10 patients with severe hepatic and abdominal injuries, acidosis and clinical 
coagulopathy(King et al., 2006). 
vi) The inorganic haemostatic based on minerals such as zeolite or smectite have been 
used and studied mainly on external bleeding (Achneck et al., 2010). 
 
 
1.2.5.1  Chitosan 
Chitosan is a copolymer consisting of β-(1→4)-2-acetamido-D-glucose and β-(1→4)-2-
amino-D-glucose units, with the latter usually exceeding 80%. The proportion of the two 
monosaccharide units in chitosan depends on the alkaline treatment. Generally, the 
individual chains assume an essentially linear structure, which undergoes one full twist 
every 10.1–10.5 Å along the chain axis. Since each monosaccharide unit is chiral, the 
rotations of polymer chains show evident left or right. Accordingly, chitosan could be 
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divided into three crystal types: α, β and γ type, which could be identified by X-ray 
model and NMR spectra. Among these, α-type is the most common type obtained from 
crust of shrimp and crab. Chitosan has three types of reactive functional groups, an 
amino/acetamido group as well as both primary and secondary hydroxyl groups at the C-
2, C-3 and C-6 positions, respectively. The amino contents are the main factors 
contributing to differences in their structures and physico-chemical properties, and its 
distribution is random, which make it easy to generate intra- and inter-molecular 
hydrogen bonds.  
 
Many novel chitosan derivatives have been obtained by chemical modification using the 
reactive activities of hydroxyl- and amino groups. In particular, the amino group has 
nucleophilic property, allowing easy formation of imine by reaction with aldehyde or 
corresponding amide derivatives in acylating reagents; in acidic solution, the amino 
groups showed alkaline properties and receive protons to generate salts, presenting 
cationic polymer properties. Besides, the amino functional group has also been correlated 
with chelation, flocculation and biological functions. The characterization of a chitosan 
sample requires the determination of its average Degree of acetylation (DA).  
 
The distribution of acetyl groups along the chain (random or block wise) may influence 
the solubility of the polymer and also the inter-chain interactions due to H-bonds and the 
hydrophobic character of the acetyl group. This distribution has been evaluated by 
various techniques such as IR, elemental analysis, enzymatic reaction, UV, 1H liquid-
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state NMR and solid-state 13C NMR. Diad and triad frequencies were determined for 
homogeneous and heterogeneous chitosan with different values of DA .  
 
Another important characteristic to consider for these polymers is the molecular weight 
and its distribution. The first difficulty encountered in this respect concerns the solubility 
of the samples and dissociation of aggregates often present in polysaccharide solutions. 
As to choice of a solvent for chitosan characterization, various systems have been 
proposed, including an acid at a given concentration for protonation together with a salt 
to screen the electrostatic interaction. The solvent is important also when molecular 
weight has to be calculated from intrinsic viscosity using the Mark-Houwink relation. 
High molecular weight chitosan is estimated to be 106. High molecular weight chitosans 
(HMWC) form solutions with higher viscosities than chitosans of lower molecular 
weight. Polymeric chitosan is soluble in acidic conditions and is insoluble at pH values 
above 6.3 (the pKa of chitosan). However, chitosan oligomer has a low viscosity, and is 
freely soluble at neutral pH.  
 
Production of low molecular weight chitosan (LMWC) and chit oligosaccharides (COS) 
from the hydrolysis of chitosan can be achieved either by chemical or enzymatic 
methods. The chemical method needs high energy and is hard to control; hence, the 
enzymatic hydrolysis of chitosan offers many advantages. During preparation of different 
molecular weight chitosans, viscosity is used as a parameter to determine the molecular 
weight. Unlike most polysaccharides, chitosan, LMWC and COS have positive charges, 
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which allows them to bind strongly to negatively charged surfaces; this property is 
responsible for many of the observed biological activities. 
 
 However, it is important to mention that chitosans with different structures show 
different biological activities, and not all biological activities are found in one kind of 
chitosan. Each special type of bioactive chitosan has been developed by chemical 
modification and enzymatic hydrolysis for its potential pharmaceutical and medical 
application(Zhang et al., 2010). It is commercially available in the US as CELOXTM 
(Med trade, Newport, OR) or HemCon® (HemCon Medical Technologies, Inc., Portland, 
OR). At this time, they are only approved by the FDA for external usage. While the 
haemostatic mechanism of this agent has not yet been fully elucidated, it has been 
proposed that its primary activity occurs via the promotion of both platelet activation and 
electrophysiological interactions between red blood cells (RBCs) and the tissue surface.  
 
Schwaitzberg et al. have found, in multiple animal protocols, that Chitosan may be 
beneficial in achieving hemostasis even in the presence of acquired or congenital 
coagulopathic disorders(Schwaitzberg et al., 2004). Klokkevold and colleagues have, 
likewise, demonstrated its effectiveness in a heparinized rabbit model(Klokkevold et al., 
1992). In that study, the investigators found that, after application of Chitosan to a lingual 
laceration, the use of this agent resulted in 43% less blood loss when compared to 
controls (p=0.001). The authors hypothesized that these results were facilitated through 
an interaction between the erythrocytes and Chitosan that resulted in a cellular 
haemostatic plug. Despite the promising results of these initial studies, further 
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investigations are needed to define the role of this agent under coagulopathic conditions, 
especially for internal usage(Recinos et al., 2008).  
 
1.2.5.2 Oxidized cellulose  
Oxidized  cellulose is commercially  available  in  the US  as  Surgicel©  and  Nu-Knit©  
(Ethicon,  Inc., Cincinnati, OH). This class of agent is intended for use as an adjunct to 
gauze packing, with their hemostatic properties primarily based on their ability to locally 
activate the coagulation cascade. While they do not contain any intrinsic coagulation 
components, they are designed to stimulate clot formation and to provide a favorable 
three-dimensional structure for clot organization. In order for these products to function, 
therefore, a functional coagulation system must be present (Table 1). 
 
 It should not be moistened before use since it exerts a greater haemostatic effect when 
applied dry. The material offers superior handling characteristics as compared with 
gelatin foams and the knitted fabric can be trimmed to fit any size. It does not stick to 
instruments and can easily be held firmly against bleeding tissue until hemostasis occurs. 
Surgicel Fibrillar® resembles cotton in consistency and remains pliable when laid into a 
wound. Either form of oxidized cellulose decreases the pH of its surroundings. This low 
pH causes red cell lyses, which explains the brown discoloration of the agent after 
contact with blood. The released hemoglobin reacts with acid to form acid hematin. One 
of the theoretical advantages of this low pH is an antimicrobial effect seen against a 
variety of pathogenic organisms(Spangler et al., 2003). Furthermore, the low pH acts as a 
caustic agent bringing about hemostasis by generating an artificial clot. Oxidized 
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cellulose disadvantage lies in the fact that the low pH inactivates other biologically active 
topical agents, such as thrombin, which limits its ability to be used in conjunction with 
other agents. Moreover, the acidic nature of Surgicel® may also increase inflammation of 
surrounding tissue and delay wound healing. The dissolution of oxidized cellulose 
depends on the amount used and ranges from 2 to 6 weeks. However, there are reports 
describing histological evidence of oxidized cellulose fibers several years after cardiac 
surgery. Moreover, cases have been reported where Surgicel® used for hemorrhage 
control during thoracotomy had passed through the intervertebral foramen and caused 
spinal cord compression(Brodbelt et al., 2002). Therefore, the smallest amount necessary 
should be used and any excess should be removed once hemostasis has been achieved. 
.  
1.2.5.3 Lyostypt (collagen) hemostat 
 
Lyostypt® is a wet-stable collagen hemostat. Collagen leads to thrombocyte adhesion 
and to activation of coagulation factor XII. Therefore, collagen is very effective in 
hemostasis. Advantages of this hemostat are rapid achievement of hemostasis, that it can 
be removed easily, applied endoscopically and that it can be combined with fibrin glue 
and antibiotics. It also can be removed easily. Collaged hemostats also do not affect cell 
growth.  Collagen should be applied to the bleeding surface with dry instruments rather 
than with the surgeon’s hands since it tends to stick to gloves. It has been used 
successfully to control wide-area parenchyma oozing(Sirlak et al., 2003).  
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In laparoscopic procedures, Endo-Avitene®, which is a rolled sheet of Collagen, is 
available with an applicator capable of placement through standard laparoscopic trocar. 
As with oxidized cellulose, we recommend removing excess Collagen from the surgical 
site after adequate hemostasis has been achieved, since it may bind to neural structures 
and cause pain or numbness. Since Collagen may pass through filters of blood 
scavenging systems, blood from operative sites where Collagen was used should not be 
returned to the patient.(Achneck et al., 2010).  
 
The purpose of this study was to compare chitosan with other commonly used 
haemostatic agents in use in surgical practice. We hypothesized that chitosan would bring 
about clotting similar or better to other haemostatic agents. In addition to that we 
hypothesized that chitosan would induce substantial platelet and rbc aggregation in 
comparison to the other haemostatic agents in a heparinized model.  
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2.0 OBJECTIVES OF STUDY 
 
2.1 General 
 
To asses the efficacy of different grades of chitosan in comparison to other common 
surgical hemostats in practice(Surgicel® and Lyostypt®). 
 
 
2.2 Specific 
i) To compare the effect of different grades of chitosan with other available,       
commonly used haemostatic agents (Lyostypt® and Surgicel® in inducing 
platelet aggregation. 
ii) To compare the haemostatic efficacy of different grades of chitosan to 
commonly available haemostatic agents ( Lyostypt® and Surgicel®) in 
altering Prothrombin and Partial Thromboplastin Time on contact with 
blood. 
iii) To compare the effect of different grades of chitosan and common 
haemostatic agents (Lyostypt® and Surgicel® ) on Red Blood Cell 
Aggregation 
    iv)  To compare the effect of different grades of chitosan and common   
haemostatic agents (Lyostypt® and Surgicel® ) in inducing hemostasis on  
induced laceration in rat kidney 
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2.3  Research hypothesis 
 
i) Chitosan is more effective compared to other available, commonly used hemostatic 
agents (Lyostypt® and Surgicel®) in inducing platelet aggregation 
ii) Chitosan in more effective compared to other available, commonly used hemostatic 
agents (Lyostypt® and Surgicel®) in altering Prothrombin time and Parial 
Thromboplastin Time on contact with blood. 
iii) Chitosan in more effective compared to other available, commonly used hemostatic 
agents (Lyostypt® and Surgicel®) in aggregating Red Blood Cells. 
iv) Chitosan in more effective compared to other available, commonly used hemostatic 
agents (Lyostypt® and Surgicel®) in inducing hemostasis on induced laceration in rat 
kidney. 
 
2.4 Null hypothesis  
 
i) Chitosan is not more effective compared to other available, commonly used hemostatic 
agents (Lyostypt® and Surgicel®) in inducing platelet aggregation 
ii) Chitosan in not more effective compared to other available, commonly used 
hemostatic agents (Lyostypt® and Surgicel®) in altering Prothrombin time and Parial 
Thromboplastin Time on contact with blood. 
iii) Chitosan in not more effective compared to other available, commonly used 
hemostatic agents (Lyostypt® and Surgicel®) in aggregating Red Blood Cells. 
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iv) Chitosan in not more effective compared to other available, commonly used 
hemostatic agents (Lyostypt® and Surgicel®) in inducing hemostasis on induced 
laceration in rat kidney. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
 
MATERIAL 
AND 
METHODS 
 
 
 
 
 
 
 
 
 22 
3.0 MATERIAL AND METHODS  
 
3.1 Outline of laboratory experiment design 
 
In this experimental study, blood sample for the study was obtained from the blood bank. 
A single healthy donor with no background medical illnesses and who was not on any 
medication for the past 6 months was chosen (Appendix 1). Blood sample was collected 
utilizing the CP2D/AS-3 systems with additive solution (AS-3, Nutricel®) to maintain 
red blood cell viability. For this study 3 types of blood products were required (Platelet 
rich plasma, Platelet poor plasma and heparinized whole blood.) 
 
3.2 Preparation of platelet poor and platelet rich plasma 
For platelet collection the blood sample was put under light spin at 900-1200Gs for 20 
min which separates the blood into two separate components (A supernatant of Platelet 
Rich Plasma and a precipitate of Packed Cells component). To further obtain Platelet 
Poor Plasma the sample of Platelet Rich Plasma was spun a second time at 3000rpm to 
produce a supernatant of Platelet Poor Plasma and Sediment of Platelets 
 
3.3 Preparation of heparinized whole blood  
Heparinized whole blood test specimens were prepared by adding heparin to blood 
specimen until Partial thromboplastin time was 3x normal. .  
 
 
 
 23 
 
 
BLOOD SAMPLE COLLECTED FROM BLOOD BANK 
 
 
 
 
 
 
 
Figure 1: Flow chart of preparation of blood samples required for individual test 
designs 
 
 
 
 
 
 
 
PT AND PTT TEST 
PLATELET RICH PLASMA AND 
PLATELET POOR PLASMA 
RBC 
SEDIMENTATION  
PLATELET RICH 
PLASMA.  
PLATELET POOR 
PLASMA AND 
HEPARINIZED 
BLOOD 
PLATELET 
AGGREGATION 
TEST 
PLATELET RICH 
PLASMA 
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3.4 Haemostatic agents used. 
In this experimental study, we used three different grades of chitosan (NoCMC 3%, 
NoCMC8% and OC52) . We also used Surgicel ® and Lyostypt ®. 
. 
3.4.1 Chitosan samples 
 
 Chitosan haemostatic agents were used in this study was obtained from Industrial 
Biotechnology Research Centre, SIRIM Berhad (Standards and Industrial Research 
Institute of Malaysia) (Figure 5 -7). 
 
3.4.2 Oxidized cellulose (Surgicel ®) 
Surgicel ® was purchased from Johnson and Johnson’s Ethicon subsidiary (Figure 8). It 
is a haemostatic agent made from oxidized cellulose polymer (polyhydroanglucoronic 
acid units. It was introduced into clinical practice in 1949. Surgicel® absorbable 
hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of 
regenerated cellulose. The fabric is white with a pale yellow cast and has a faint caramel-
like aroma. It is strong and can be sutured or cut without fraying. After Surgicel® has 
been saturated with blood; it swells into a brownish or black gelatinous mass which aids 
in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local 
hemorrhage.  
 
 
